Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer

医学 列线图 前列腺切除术 前列腺癌 生化复发 阶段(地层学) 手术切缘 前列腺特异性抗原 根治性耻骨后前列腺切除术 活检 泌尿科 癌症 淋巴结 比例危险模型 前列腺 局限性疾病 外科 肿瘤科 内科学 古生物学 生物
作者
Michael W. Kattan,Thomas M. Wheeler,Peter T. Scardino
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:17 (5): 1499-1499 被引量:683
标识
DOI:10.1200/jco.1999.17.5.1499
摘要

PURPOSE: Although models exist that place patients into discrete groups at various risks for disease recurrence after surgery for prostate cancer, we know of no published work that combines pathologic factors to predict an individual's probability of disease recurrence. Because clinical stage and biopsy Gleason grade only approximate pathologic stage and Gleason grade in the prostatectomy specimen, prediction of prognosis should be more accurate when postoperative information is added to preoperative variables. Therefore, we developed a postoperative nomogram that allows more accurate prediction of probability for disease recurrence for patients who have received radical prostatectomy as treatment for prostate cancer, compared with the preoperative nomogram we previously published. PATIENTS AND METHODS: By Cox proportional hazards regression analysis, we modeled the clinical and pathologic data and disease follow-up for 996 men with clinical stage T1a-T3c NXM0 prostate cancer who were treated with radical prostatectomy by a single surgeon at our institution. Prognostic variables included pretreatment serum prostate-specific antigen level, specimen Gleason sum, prostatic capsular invasion, surgical margin status, seminal vesicle invasion, and lymph node status. Treatment failure was recorded when there was either clinical evidence of disease recurrence, a rising serum prostate-specific antigen level (two measurements of 0.4 ng/mL or greater and rising), or initiation of adjuvant therapy. Validation was performed on this set of men and a separate sample of 322 men from five other surgeons' practices from our institution. RESULTS: Cancer recurrence was noted in 189 of the 996 men, and the recurrence-free group had a median follow-up period of 37 months (range, 1 to 168 months). The 7-year recurrence-free probability for the cohort was 73% (95% confidence interval, 68% to 76%). The predictions from the nomogram appeared to be accurate and discriminating, with a validation sample area under the receiver operating characteristic curve (ie, a comparison of the predicted probability with the actual outcome) of 0.89. CONCLUSION: A postoperative nomogram has been developed that can be used to predict the 7-year probability of disease recurrence among men treated with radical prostatectomy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一一完成签到,获得积分10
1秒前
蓝冰发布了新的文献求助10
1秒前
lgj发布了新的文献求助10
1秒前
1秒前
陈sir完成签到,获得积分10
1秒前
2秒前
2秒前
李健应助余可馨采纳,获得10
2秒前
3秒前
大气的南松完成签到,获得积分10
3秒前
桐桐应助啊楠采纳,获得30
4秒前
煜琪发布了新的文献求助10
5秒前
研友_VZG7GZ应助大脚丫采纳,获得10
5秒前
所所应助Yen采纳,获得10
5秒前
6秒前
英勇代荷完成签到,获得积分10
6秒前
6秒前
lgj完成签到,获得积分20
7秒前
刻苦的晓蕾完成签到,获得积分10
7秒前
打打应助lllll采纳,获得10
7秒前
7秒前
7秒前
dark完成签到,获得积分10
7秒前
甜蜜的书白完成签到,获得积分10
8秒前
奋斗的怀曼完成签到,获得积分10
8秒前
在水一方应助hml采纳,获得10
8秒前
慢波发布了新的文献求助10
8秒前
科研小白完成签到,获得积分10
9秒前
阳光念烟发布了新的文献求助10
9秒前
Akim应助lieditongxu采纳,获得10
9秒前
阿敬完成签到,获得积分10
9秒前
123发布了新的文献求助10
9秒前
GJP完成签到,获得积分10
9秒前
10秒前
885791403完成签到 ,获得积分10
10秒前
10秒前
我要发nature完成签到,获得积分10
10秒前
愉快的宛儿完成签到,获得积分20
10秒前
风趣夜云发布了新的文献求助10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
晶种分解过程与铝酸钠溶液混合强度关系的探讨 8888
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6421583
求助须知:如何正确求助?哪些是违规求助? 8240602
关于积分的说明 17513705
捐赠科研通 5475445
什么是DOI,文献DOI怎么找? 2892465
邀请新用户注册赠送积分活动 1868848
关于科研通互助平台的介绍 1706227